The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35

Liu, Pei Y.; Milazzo, Giorgio; Hannan, Katherine M.; Mååg, Jesper L.V.; Mondal, Sujanna; Atmadibrata, Bernard; Bartoniček, Nenad; Peng, Hui; Ho, Nicholas; Mayoh, Chelsea; Ciaccio, Roberto; Sun, Yuting; Henderson, Michelle J.; Gao, Jixuan; Everaert, Celine; Hulme, Amy E.; Tee, Andrew E.; Lan, Qing; Cheung, Belamy B.; Shi, Leming; Wang, Jenny; Simon, Thorsten; Fischer, Matthias; Zhang, Xu Dong; Marshall, Glenn M.; Norris, Murray D.; Haber, Michelle; Vandesompele, Jo; Li, Jinyan; Mestdagh, Pieter; Hannan, Ross D.; Dinger, Marcel E.; Perini, Giovanni; Liu, Tao

doi:10.1038/s41467-019-12971-3

Cited by 70 publications

(77 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vitro enforced expression of RPL22L1 increased tumorigenicity and mesenchymal markers. In our analysis, RPL35 was also associated with MNA tumours and reportedly plays an important role in neuroblastoma [23]. Specifically, RPL35 protein bound lncNB1 (a long non-coding RNA) and E2F1 mRNA and facilitated E2F1 mRNA translation into protein, leading to increased DEPDC1B gene transcription.…”

Section: Ribosomal Proteins: Rpl22l1 Rpl39 Rpl18a Rpl36 Rpl35 Rps3mentioning

confidence: 65%

“…The binding of IGF2BPs to RNA relies on the m 6 A RNA epi-transcriptomic modification [ 58 ]. All family members are reported to be expressed in up to 100% of neuroblastoma tumours, with high IGF2BP1 expression associated with poor overall prognosis and MYCN amplification [ 59 ], as well as MNA cell lines [ 23 ]. In our analyses, IGF2BP1 was highly expressed in MNA tumours, though the significance was lower than the top elucidated candidates discussed here.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Identification of RNA-Binding Proteins as Targetable Putative Oncogenes in Neuroblastoma

Bell

Hagemann

Holien

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

Neuroblastoma is a common childhood cancer with almost a third of those affected still dying, thus new therapeutic strategies need to be explored. Current experimental therapies focus mostly on inhibiting oncogenic transcription factor signalling. Although LIN28B, DICER and other RNA-binding proteins (RBPs) have reported roles in neuroblastoma development and patient outcome, the role of RBPs in neuroblastoma is relatively unstudied. In order to elucidate novel RBPs involved in MYCN-amplified and other high-risk neuroblastoma subtypes, we performed differential mRNA expression analysis of RBPs in a large primary tumour cohort (n = 498). Additionally, we found via Kaplan–Meier scanning analysis that 685 of the 1483 tested RBPs have prognostic value in neuroblastoma. For the top putative oncogenic candidates, we analysed their expression in neuroblastoma cell lines, as well as summarised their characteristics and existence of chemical inhibitors. Moreover, to help explain their association with neuroblastoma subtypes, we reviewed candidate RBPs’ potential as biomarkers, and their mechanistic roles in neuronal and cancer contexts. We found several highly significant RBPs including RPL22L1, RNASEH2A, PTRH2, MRPL11 and AFF2, which remain uncharacterised in neuroblastoma. Although not all RBPs appear suitable for drug design, or carry prognostic significance, we show that several RBPs have strong rationale for inhibition and mechanistic studies, representing an alternative, but nonetheless promising therapeutic strategy in neuroblastoma treatment.

show abstract

Section: Ribosomal Proteins: Rpl22l1 Rpl39 Rpl18a Rpl36 Rpl35 Rps3mentioning

confidence: 65%

Section: Resultsmentioning

confidence: 99%

Identification of RNA-Binding Proteins as Targetable Putative Oncogenes in Neuroblastoma

Bell

Hagemann

Holien

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…LncRNAs suppress (Rinn et al, 2007;Kaneko et al, 2014;Kim et al, 2018) or activate (Wang et al, 2011;Gomez et al, 2013;Luo et al, 2019; gene transcription by binding to chromatin remodeling protein complexes and by acting as transcriptional enhancers (Lai et al, 2013;Jiang et al, 2018). In addition, lncRNAs post-transcriptionally regulate mRNAs, such as pre-mRNA alternative splicing (Beltran et al, 2008;Andersen et al, 2019), mRNA stability (Yang et al, 2014;Liu et al, 2014), and translation into proteins (Yoon et al, 2012;Malakar et al, 2019;Liu et al, 2019).…”

Section: Introduction Long Noncoding Rnasmentioning

confidence: 99%

The Oncogenic and Tumor Suppressive Functions of the Long Noncoding RNA MALAT1: An Emerging Controversy

2020

View full text Add to dashboard Cite

Long noncoding RNAs are recently emerging as critical factors of tumorigenesis. Originally regarded as a pre-messenger RNA (mRNA) splicing regulator, the long noncoding RNA MALAT1 has been demonstrated to regulate gene transcription by binding histone modification enzymes and transcription factors, and to regulate mRNA and protein expression post-transcriptionally by binding microRNAs (miRNAs) and acting as a sponge. Early studies consistently report that MALAT1 is up-regulated in human cancer tissues of various organ origins, particularly metastatic cancer tissues, that high levels of MALAT1 expression in cancer tissues are associated with poor patient prognosis, and that MALAT1 induces cancer cell proliferation, migration, and invasion in vitro and tumor metastasis in mice. By contrast, by analyzing multiple independent large datasets, MALAT1 have very recently been found to be down-regulated in human colorectal and breast cancer tissues, and low MALAT1 expression is associated with decreased patient survival. By binding to the transcription factor TEAD, MALAT1 suppresses metastasis gene expression, colorectal and breast cancer cell migration, invasion, and metastasis in vitro and in mice. MALAT1 has therefore been proposed to function as a tumor suppressor in colorectal and breast cancers. More comprehensive studies with multiple independent cohorts of human cancer tissues of various organ origins, in vitro and in vivo function, and mechanism studies with rescue experiments are required to confirm the oncogenic or tumor suppressive role of MALAT1 in other cancers.

show abstract

“…RPS20 was identi ed as a new oncogene in glioblastoma [30] and colon cancer [31]. RPL35 was identi ed as an key factors for tumorigenesis in neuroblastoma [32]. RPS2 was overexpressed in malignant prostate cancer and had the potential to be therapeutic target for prostate cancer [33].…”

Section: Discussionmentioning

confidence: 99%

Integrated analysis of the functions of RNA binding proteins in clear cell renal cell carcinoma

Hua¹,

Chen

Ge³

et al. 2021

Genomics

View full text Add to dashboard Cite

Background: RNA binding proteins (RBPs) dysregulation is involved in the process es of various tumor. However, the roles of RBPs in clear cell renal cell carcinoma (ccRCC) remain poorly understand. Systematic exploration of the roles of RBPs in ccRCC may provide new insights for the treatments of ccRCC. Methods: Expression data of RBPs was obtained from The Cancer Genome Atlas database. The roles of RBPs in ccRCC were systematically investigated using consensus clustering methods. Differentially expressed RBPs between normal and tumor tissues were obtained. Protein-protein interaction (PPI) network was constructed using "STRING" software. The expression levels of hub genes were validated in The Human Protein Atlas (HPA) database and receiver operating characteristic (ROC) curves were used to evaluate diagnostic value. Univariate and Lasso Cox regression and Kaplan-Meier curves were used to screen the most useful prognostic genes. Multivariate Cox regression was performed to construct a risk score model. The e ciency of the model was evaluated using time-dependent ROC and Kaplan-Meier curves, and validated in E-MTAB-3267 set. Results: Two clusters were identi ed based on the expression similarity of RBPs, and the cluster 2 was closely correlated with the malignancy of ccRCC. Several oncogenic pathways, including epithelial mesenchymal transition, G2M checkpoint, KRAS signaling and IL6 JAK STAT3 signaling were enriched in cluster 2. In addition, we obtained 115 differently expressed RBPs in ccRCC, comprising 71 up-regulated and 44 down-regulated ones. Ten hub RBPs with good diagnostic value were obtained from PPI network and validated in HPA database. Ten RBPs were identi ed as survival-related genes and used to construct a risk score model. The model could be used to stratify patients with different prognosis. We found highrisk patients tended to be advanced stage, high grade, high pathological T staging and could be an independent risk factor for overall survival of ccRCC patients. Conclusions: We identi ed ten RBPs with diagnostic value, which might be the potential diagnostic biomarkers for ccRCC. A risk score model was established to stratify patients and could be used as a complementation for clinical factors to guide clinical practice in the future.

show abstract

The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35

Cited by 70 publications

References 47 publications

Identification of RNA-Binding Proteins as Targetable Putative Oncogenes in Neuroblastoma

Identification of RNA-Binding Proteins as Targetable Putative Oncogenes in Neuroblastoma

The Oncogenic and Tumor Suppressive Functions of the Long Noncoding RNA MALAT1: An Emerging Controversy

Integrated analysis of the functions of RNA binding proteins in clear cell renal cell carcinoma

Contact Info

Product

Resources

About